Companion Diagnostics Development Services Market, 2020-2030

Overview

Personalized medicine has brought about a paradigm shift within the healthcare sector. However, therapies tailored to specific disease-related molecular signatures require appropriate companion diagnostics in order to make physicians aware of patients’ unique genetic profiles, enabling them to make informed treatment related decisions. In fact, a clinical study of nearly 200 unique pharmacological interventions, which were evaluated across more than 670 clinical trials, suggests that the likelihood of a lead compound passing through various phases of clinical development and eventually getting approved is only 11%. The same study pointed out that using disease-specific biomarker information (indicative of susceptibility to particular types of therapeutics) to recruit patients for clinical research has been associated with a manifold increase in trial success rates. In addition, it is worth noting that companion diagnostics guided drug development efforts have demonstrated to effectively reduce clinical trial costs by almost 60%.

Given the aforementioned advantages, the industry is gradually shifting from the traditional, one-drug-for-all, paradigm to using tailored pharmacological interventions. This shift is subsequently expected to increase the demand for companion diagnostics. However, given the complexity associated with the co-development of a drug and a corresponding companion diagnostic test, pharmaceutical developers have shown preference to outsource the diagnostics development operations. In fact, nearly 80% of the companies are known to rely on external diagnostics developers for companion diagnostics development, mostly owing to the lack of in-house expertise. As a result, numerous contract service providers are striving to expand their respective portfolios and developing the capabilities to offer end-to-end services to sponsor companies in this domain. Amidst tough competition, the availability of cutting-edge tools and technologies (such as in situ hybridization (ISH), immunohistochemistry (IHC), next generation sequencing (NGS), polymerase chain reaction (PCR)) has emerged as a differentiating factor and is likely to grant a competitive advantage to certain service providers over other players in the industry.

Scope of the Report

The “Companion Diagnostics Development Services Market, 2020-2030” report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of diagnostic development services over the next decade. It features an in-depth analysis, highlighting the capabilities of the various stakeholders in this domain. In addition to other elements, the study includes:

A detailed assessment of the current market landscape of companies offering companion diagnostics services, including information on the type of services offered, type of analytical technique used and regulatory certifications / accreditations, and other company-specific details (such as year of establishment, company size and geographical location).
Tabulated profiles of companion diagnostics service providers (shortlisted on the basis of the number of services offered), featuring an overview of the company, its financial information (if available), and companion diagnostics-related service portfolio details. In addition, each profile includes a list of the likely strategies that may be adopted by these players to support future growth.
An analysis of the partnerships and collaborations pertaining to companion diagnostics services from 2017 to 2019, featuring a detailed set of analyses based on various parameters, such as the type of partnership, year of partnership, analytical technique used and the most active players.
A list of stakeholders generated based on a detailed analysis of a set of relevant parameters (namely number of clinical trials sponsored by a developer and the time to market for proprietary personalized medicine products), which are anticipated to partner with companion diagnostics services providers in the foreseen future.
A detailed competitiveness analysis of companion diagnostics services providers, taking into consideration the supplier power (based on the year of establishment of developer) and key specifications, such as portfolio strength, type of available technology platform, number of deals signed between 2017-2019.
A comparative analysis of the needs of different stakeholders (drug developers, diagnostic developers, testing laboratories, physicians, payers and patients) involved in this domain.
A discussion on various steps of the development operations, namely research and development, clinical assessment of the product, manufacturing and assembly, payer negotiation and marketing / sales activities, of a companion diagnostic and the cost requirements across each of the aforementioned stages.
An analysis of completed, ongoing and planned clinical trials featuring disease-specific biomarkers. The analysis highlights the key trends associated with these clinical studies across various parameters, such as trial start year, trial status, phase of development, key indications, type of therapy, biomarkers evaluated, enrolled patient population and regional distribution of trials.

One of the key objectives of the report was to estimate the existing market size and the future opportunity for companion diagnostic services providers, over the next decade. Based on multiple parameters, we have provided informed estimates on the evolution of the market for the period 2020-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] key services offered (biomarker discovery, assay development, clinical validation, analytical validation and manufacturing), [B] analytical techniques used (ISH, IHC, NGS, PCR and others), and [C] key geographical regions (North America, Europe, Asia and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry.

The report features detailed transcripts of discussions held with the following industry stakeholders:

Pablo Ortiz (Chief Executive Officer, OWL Metabolomics)
Paul Kortschak (Senior Vice President, Novodiax)
Lawrence M. Weiss (Chief Scientific Officer, NeoGenomics Laboratories)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

1. PREFACE

1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Chapter Overview
3.2. Evolution of Personalized Medicine
3.3. Overview of Companion Diagnostics
3.3.1. Development of Companion Diagnostics
3.3.2. Analytical Techniques Used in Companion Diagnostic Tests
3.3.2.1. Immunohistochemistry
3.3.2.2. In situ Hybridization
3.3.2.3. Polymerase Chain Reaction
3.3.2.4. DNA Sequencing / Next Generation Sequencing
3.3.3. Advantages of Companion Diagnostics
3.4. Applications of Companion Diagnostics across Different Therapeutic Areas
3.4.1. Oncology
3.4.2. Infectious Diseases
3.4.3. Neurological Disorders
3.5. Regulatory Review and Approval Process for Companion Diagnostics
3.6. Existing Challenges
3.7. Future Roadmap

4. MARKET LANDSCAPE

4.1. Chapter Overview
4.2. Companion Diagnostics Service Providers: Overall Market Landscape
4.2.1 Analysis by Type of Service Offered
4.2.2. Analysis by Type of Analytical Technique
4.2.3. Analysis by Regulatory Accreditation / Certification
4.2.4. Analysis by Type of End User
4.3. Companion Diagnostics Service Providers: Developer Landscape
4.3.1 Analysis by Year of Establishment
4.3.2 Analysis by Company Size
4.3.3 Analysis by Geographical Location
4.3.4 Grid Representation: Analysis by Type of Service Offered, Company Size, and Geographical Location
4.3.5 World Map Representation: Analysis by Geography

5. COMPANY PROFILES

5.1. Chapter Overview
5.2. Key Players in North America
5.2.1. Asuragen
5.2.1.1. Recent Developments and Future Outlook
5.2.2. Covance
5.2.2.1. Recent Developments and Future Outlook
5.2.3. Geneuity
5.2.3.1. Recent Developments and Future Outlook
5.2.4. MD Biosciences
5.2.4.1. Recent Developments and Future Outlook
5.2.5. ResearchDx
5.2.5.1. Recent Developments and Future Outlook
5.3. Players in Europe
5.3.1. Almac Diagnostic Services
5.3.1.1. Recent Developments and Future Outlook
5.3.2. Leica Biosystems
5.3.2.1. Recent Developments and Future Outlook
5.3.3. R-Biopharm
5.3.3.1. Recent Developments and Future Outlook
5.3.4. Tepnel Pharma Services
5.3.4.1. Recent Developments and Future Outlook
5.4. Key Players in Asia-Pacific
5.4.1. BARD1 Life Sciences
5.4.1.1. Recent Developments and Future Outlook
5.4.2. BioMarCare Technologies
5.4.2.1. Recent Developments and Future Outlook
5.4.3. Gencurix
5.4.3.1. Recent Developments and Future Outlook
5.4.4. Macrogen
5.4.4.1. Recent Developments and Future Outlook

6. PARTNERSHIPS AND COLLABORATIONS

6.1 Chapter Overview
6.2 Partnership Models
6.3 List of Partnerships and Collaborations
6.3.1 Analysis by Year of Partnership
6.3.2 Analysis by Type of Partnership
6.3.3 Analysis by Type of Analytical Technique
6.3.4 Analysis by Type of Therapeutic Area
6.3.5 Analysis by Year of Partnership and Type of Partner
6.3.6 Analysis by Type of Partnership and Type of Partner
6.3.7 Most Active Players: Analysis by Number of Partnerships
6.3.8 Popular Analytical Techniques: Analysis by Number of Partnerships
6.3.9 Regional Analysis
6.3.10 Intercontinental and Intracontinental Agreements

7. LIKELY PARTNER ANALYSIS

7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Scoring Criteria and Key Assumptions
7.4. Likely Partners for Companion Diagnostics Service Providers: Alzheimer’s Disease
7.4.1. Companies Working on the Amyloid Beta Biomarker
7.4.1.1. World Map Representation: Amyloid Beta Biomarker Focused Clinical Trials
7.4.2. Companies Working on the Tau Biomarker
7.4.2.1. World Map Representation: Tau Biomarker Focused Clinical Trials
7.5. Likely Partners for Companion Diagnostics Service Providers: Breast Cancer
7.5.1. Companies Working on the BRCA Biomarker
7.5.1.1. World Map Representation: BRCA Biomarker Focused Clinical Trials
7.5.2. Companies Working on the HER Biomarker
7.5.2.1. World Map Representation: HER Biomarker Focused Clinical Trials
7.5.3. Companies Working on the HR Biomarker
7.5.3.1. World Map Representation: HR Biomarker Focused Clinical Trials
7.5.4. Companies Working on the PD-L1 Biomarker
7.5.4.1. World Map Representation: PD-L1 Biomarker Focused Clinical Trials
7.6. Likely Partners for Companion Diagnostics Service Providers: Colorectal Cancer
7.6.1. Companies Working on the BRAF Biomarker
7.6.1.1. World Map Representation: BRAF Biomarker Focused Clinical Trials
7.6.2. Companies Working on the EGFR Biomarker
7.6.2.1. World Map Representation: EGFR Biomarker Focused Clinical Trials
7.6.3. Companies Working on the KRAS Biomarker
7.6.3.1. World Map Representation: KRAS Biomarker Focused Clinical Trials
7.6.4. Companies Working on the MSI Biomarker
7.6.4.1. World Map Representation: MSI Biomarker Focused Clinical Trials
7.6.5. Companies Working on the NRAS Biomarker
7.6.5.1. World Map Representation: NRAS Biomarker Focused Clinical Trials
7.7. Likely Partners for Companion Diagnostic Service Providers: HIV
7.7.1. Companies Working on the CCR5 Biomarker
7.7.1.1. World Map Representation: CCR5 Biomarker Focused Clinical Trials
7.8. Likely Partners for Companion Diagnostics Service Providers: Lung Cancer
7.8.1. Companies Working on the ALK Biomarker
7.8.1.1. World Map Representation: ALK Biomarker Focused Clinical Trials
7.8.2. Companies Working on the EGFR Biomarker
7.8.2.1. World Map Representation: EGFR Biomarker Focused Clinical Trials
7.8.3. Companies Working on the PD-L1 Biomarker
7.8.3.1. World Map Representation: PD-L1 Biomarker Focused Clinical Trials
7.8.4. Companies Working on the ROS Biomarker
7.8.4.1. World Map Representation: ROS Biomarker Focused Clinical Trials
7.9. Likely Partners for Companion Diagnostics Service Providers: NASH / NAFLD
7.9.1. Companies Working on the AST Biomarker
7.9.1.1. World Map Representation: AST Biomarker Focused Clinical Trials
7.10. Likely Partners for Companion Diagnostics Service Providers: Ovarian Cancer
7.10.1. Companies Working on the BRCA Biomarker
7.10.1.1. World Map Representation: BRCA Biomarker Focused Clinical Trials
7.10.2. Companies Working on the CA-125 Biomarker
7.10.2.1. World Map Representation: CA-125 Biomarker Focused Clinical Trials
7.11. Likely Partners for Companion Diagnostics Service Providers: Prostate Cancer
7.11.1. Companies Working on the PTEN Biomarker
7.11.1.1. World Map Representation: PTEN Biomarker Focused Clinical Trials

8. COMPANY COMPETITIVENESS ANALYSIS

8.1 Chapter Overview
8.2 Methodology
8.3 Assumptions and Key Parameters
8.4 Company Competitiveness Analysis
8.4.1 Companion Diagnostics Service Providers based in North America
8.4.2 Companion Diagnostics Service Providers based in Europe
8.4.3 Companion Diagnostics Service Providers based in Asia Pacific / RoW

9. STAKEHOLDER NEEDS ANALYSIS

9.1. Chapter Overview
9.2. Companion Diagnostics: Needs of Different Stakeholders
9.3. Comparison of Needs of Various Stakeholders
9.3.1. Needs of Drug Developers
9.3.2. Needs of Companion Diagnostics Developers
9.3.3. Needs of Regulatory Authorities
9.3.4. Needs of Testing Laboratories
9.3.5. Needs of Payers / Insurance Providers
9.3.6. Needs of Physicians
9.3.7. Needs of Patients

10. VALUE CHAIN ANALYSIS

10.1. Chapter Overview
10.2. Companion Diagnostics Value Chain: Cost Distribution
10.2.1. Research and Product Development
10.2.2. Manufacturing and Assembly
10.2.3. Clinical Trials, FDA Approval and Other Administrative Tasks
10.2.4. Payer Negotiation and KOL Engagement
10.2.5. Marketing and Sales
10.3. Companion Diagnostics Development Operations: Key Cost Contributors
10.4. Companion Diagnostics Co-Development Operations: Key Cost Contributors

11. CLINICAL RESEARCH ON CANCER BIOMARKERS: BIG PHARMA PERSPECTIVE

11.1. Chapter Overview
11.2. Methodology
11.3. Clinical Trial Analysis
11.3.1. List of Likely Drug Candidates for IVD Developers
11.4. Cumulative Distribution of Biomarker Focused Trials by Registration Year, 2016-2019
11.4.1. Analysis of Trials for Most Popular Biomarkers
11.4.2. Analysis of Trials for Moderately Popular Biomarkers
11.4.3. Analysis of Trials for Less Popular / Preliminary Stage Biomarkers
11.4.4. Other Emerging Biomarkers: Word Cloud
11.4.5. Cumulative Distribution of Trials of the Most Popular Biomarkers by Registration Year
11.4.6. Cumulative Distribution of Trials of the Moderately Popular Biomarkers by Registration Year
11.4.7. Cumulative Distribution of Trials of the Less Popular Biomarkers by Registration Year
11.5. Analysis of Biomarker Focused Trials for Most Popular Indications
11.5.1. Analysis of Trials for Moderately Popular Indications
11.5.2. Analysis of Trials for Less Popular and Other Indications
11.5.3. Other Emerging Indications: Word Cloud
11.5.4. Cumulative Distribution of Trials of the Most Popular Indications by Registration Year
11.5.5. Cumulative Distribution of Trials of the Moderately Popular Indications by Registration Year
11.5.6. Cumulative Distribution of Trials of the Less Popular / Preliminary Stage Indications by Registration Year
11.6. Analysis of Biomarker Focused Trials by Phase of Development
11.6.1. Analysis of Trials of the Most Popular Biomarkers
11.6.2. Analysis of Trials of the Moderately Popular Biomarkers
11.6.3. Analysis of Trials of the Less Popular and Other Biomarkers
11.6.4. Analysis of Trials of the Most Popular Indications
11.6.5. Analysis of Trials of the Moderately Popular Indications
11.6.6. Analysis of Trials of the Less Popular and Other Indications
11.7. Analysis of Biomarker Focused Trials by Sponsor
11.7.1. Analysis of Trials of the Most Popular Biomarkers
11.7.2. Analysis of Trials of the Moderately Popular Biomarkers
11.7.3. Analysis of Trials of the Most Popular Indications
11.7.4. Analysis of Trials of the Moderately Popular Indications
11.8. Analysis of Biomarker Focused Trials by Recruitment Status
11.9. Analysis of Biomarker Focused Trials by Therapy Design
11.10. Analysis of Biomarker Focused Trials by Geography
11.10.1. Analysis of Trials by Phase of Development and Recruitment Status
11.11. Clinical Trials Summary: Analysis of Biomarker Focused Trials by Most Popular Indications
11.12. Clinical Trials Summary: Analysis of Biomarker Focused Trials by Moderately Popular Indications
11.13. Clinical Trials Summary: Analysis of Biomarker Focused Trials by Preliminary Stage Indications

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS

12.1. Chapter Overview
12.2. Key Assumptions and Forecast Methodology
12.3. Global Companion Diagnostics Services Market, 2020-2030
12.3.1. Global Companion Diagnostics Services Market: Distribution by Type of Service Offered, 2020-2030
12.3.2. Global Companion Diagnostics Services Market: Distribution by Type of Analytical Technique, 2020-2030
12.3.3. Global Companion Diagnostics Services Market: Distribution by Region, 2020-2030
12.4. Companion Diagnostics Services Market in the North America, 2020-2030
12.4.1. Companion Diagnostics Services Market in the North America: Distribution by Type of Service Offered, 2020-2030
12.4.2. Companion Diagnostics Services Market in the North America: Distribution by Type of Analytical Technique, 2020-2030
12.5. Companion Diagnostics Services Market in Europe, 2020-2030
12.5.1. Companion Diagnostics Services Market in Europe: Distribution by Type of Service Offered, 2020-2030
12.5.2. Companion Diagnostics Services Market in Europe: Distribution by Type of Analytical Technique, 2020-2030
12.6. Companion Diagnostics Services Market in Asia, 2020-2030
12.6.1. Companion Diagnostics Services Market in Asia: Distribution by Type of Service Offered, 2020-2030
12.6.2. Companion Diagnostics Services Market in Asia: Distribution by Type of Analytical Technique, 2020-2030
12.7. Companion Diagnostics Services Market in Rest of the World, 2020-2030
12.7.1. Companion Diagnostics Services Market in Rest of the World: Distribution by Type of Service Offered, 2020-2030
12.7.2. Companion Diagnostics Services Market in Rest of the World: Distribution by Type of Analytical Technique, 2020-2030

13. EXECUTIVE INSIGHTS

13.1. Chapter Overview
13.2. OWL Metabolomics
13.2.1. Company Snapshot
13.2.2. Interview Transcript: Pablo Ortiz, Chief Executive Officer
13.3. Novodiax
13.3.1 Company Snapshot
13.3.2. Interview Transcript: Paul Kortschak, Senior Vice President

14. CONCLUDING REMARKS15. APPENDIX 1: TABULATED DATA16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1 Evolution of Personalized Medicine, 2012-2017
Figure 3.2 Preclinical Development of Biomarker-based Targeted Therapies
Figure 3.3 Role of Companion Diagnostics in Clinical Trials
Figure 3.4 Companion Diagnostics: Key Advantages
Figure 3.5 Companion Diagnostics: Primary Development-related Challenges
Figure 3.6 Companion Diagnostics: Market Drivers and Constraints
Figure 4.1 Companion Diagnostics Service Providers: Distribution by Type of Service Offered
Figure 4.2 Companion Diagnostics Service Providers: Distribution by Type of Analytical Technique
Figure 4.3 Companion Diagnostics Service Providers: Distribution by Type of Regulatory Accreditation / Certification
Figure 4.4 Companion Diagnostics Service Providers: Distribution by Type of End User
Figure 4.5 Companion Diagnostics Service Providers: Distribution by Year of Establishment
Figure 4.6 Companion Diagnostics Service Providers: Distribution by Company Size
Figure 4.7 Companion Diagnostics Service Providers: Distribution by Geographical Location
Figure 4.8 Grid Representation: Distribution by Type of Service Offered, Company Size, and Geographical Location
Figure 4.9 World Map Representation: Analysis by Geography
Figure 6.1. Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2019
Figure 6.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 6.3. Partnerships and Collaborations: Year-wise Trend by Type of Partnership 2017-2019.
Figure 6.4. Partnerships and Collaborations: Distribution by Type of Analytical Technique and Type of Partnership
Figure 6.5. Partnerships and Collaborations: Distribution by Type of Therapeutic Area and Type of Partnership
Figure 6.6. Partnerships and Collaborations: Year-wise Trend for Type of Partner
Figure 6.7. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 6.8. Most Active Players: Distribution by Number of Partnerships
Figure 6.9. Partnership and Collaborations: Regional Distribution
Figure 6.10. Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 7.1. World Map Representation: Distribution of Amyloid Beta Biomarker Focused Clinical Trials
Figure 7.2. World Map Representation: Distribution of Tau Biomarker Focused Clinical Trials
Figure 7.3. World Map Representation: Distribution of BRCA Focused Clinical Trials
Figure 7.4. World Map Representation: Distribution of HER Focused Clinical Trials
Figure 7.5. World Map Representation: Distribution of HR Focused Clinical Trials
Figure 7.6. World Map Representation: Distribution of PD-L1 Focused Clinical Trials
Figure 7.7. World Map Representation: Distribution of BRAF Focused Clinical Trials
Figure 7.8. World Map Representation: Distribution of EGFR Focused Clinical Trials
Figure 7.9. World Map Representation: Distribution of KRAS Focused Clinical Trials
Figure 7.10. World Map Representation: Distribution of MSI Focused Clinical Trials
Figure 7.11. World Map Representation: Distribution of NRAS Focused Clinical Trials
Figure 7.12. World Map Representation: Distribution of CCR5 Focused Clinical Trials
Figure 7.13. World Map Representation: Distribution of ALK Focused Clinical Trials
Figure 7.14. World Map Representation: Distribution of EGFR Focused Clinical Trials
Figure 7.15. World Map Representation: Distribution of PD-L1 Focused Clinical Trials
Figure 7.16. World Map Representation: Distribution of ROS Focused Clinical Trials
Figure 7.17. World Map Representation: Distribution of AST Focused Clinical Trials
Figure 7.18. World Map Representation: Distribution of BRCA Focused Clinical Trials
Figure 7.19. World Map Representation: Distribution of CA-125 Focused Clinical Trials
Figure 7.20. World Map Representation: Distribution of PTEN Focused Clinical Trials
Figure 8.1. Competitiveness Analysis: Companion Diagnostics Service Providers Based in North America
Figure 8.2. Competitiveness Analysis: Companion Diagnostics Service Providers Based in Europe
Figure 8.3. Competitiveness Analysis: Companion Diagnostics Service Providers Based in Asia Pacific / RoW
Figure 9.1. Stakeholder Needs Analysis: Comparison of Needs of Different Stakeholders
Figure 9.2. Stakeholder Needs Analysis: Comparison of Needs of Various Stakeholders Stakeholder Needs Analysis: Comparison of Needs of Various Stakeholders
Figure 9.3. Stakeholder Needs Analysis: Comparison of Needs of Companion Diagnostics Stakeholder Needs Analysis: Comparison of Needs of Companion Diagnostics Developers
Figure 9.4. Stakeholder Needs Analysis: Needs of Regulatory Authorities
Figure 9.5. Stakeholder Needs Analysis: Needs of Testing Laboratories
Figure 9.6. Stakeholder Needs Analysis: Needs of Payers / Insurance Providers
Figure 9.7. Stakeholder Needs Analysis: Needs of Physicians
Figure 9.8. Stakeholder Needs Analysis: Needs of Patients
Figure 10.1 Companion Diagnostics Value Chain: Cost Distribution
Figure 10.2 Companion Diagnostics Value Chain: Research and Product Development
Figure 10.3 Companion Diagnostics Value Chain: Manufacturing and Assembly
Figure 10.4 Companion Diagnostics Value Chain: Clinical Trials, FDA Approval and Other Administrative Tasks
Figure 10.5 Companion Diagnostics Value Chain: Payer Negotiation and KOL Engagement
Figure 10.6 Companion Diagnostics Value Chain: Marketing and Sales
Figure 10.7 Companion Diagnostics Development Operations: Key Cost Contributors
Figure 10.8 Companion Diagnostics Co-Development Operations: Key Cost Contributors
Figure 11.1 Clinical Trial Analysis: Distribution by Trial Registration Year
Figure 11.2 Clinical Trial Analysis: Distribution of Trials of the Most Popular Biomarkers by Trial Registration Year
Figure 11.3 Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Biomarkers by Trials Registration Year
Figure 11.4 Clinical Trial Analysis: Distribution of Trials of the Less Popular / Preliminary Stage Biomarkers by Trial Registration Year
Figure 11.5 Other Emerging Biomarkers: Word Cloud
Figure 11.6 Clinical Trial Analysis: Distribution of Trials of the Most Popular Biomarkers by Trial Registration Year
Figure 11.7 Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Biomarkers by Trial Registration Year
Figure 11.8 Clinical Trial Analysis: Distribution of Trials of the Less Popular and Other Biomarkers by Trial Registration Year
Figure 11.9 Clinical Trial Analysis: Distribution by Most Popular Indications
Figure 11.10 Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Indications
Figure 11.11 Clinical Trial Analysis: Distribution of Trials of the Less Popular and Other Indications
Figure 11.12 Less Popular and Other Indications: Word Cloud
Figure 11.13 Clinical Trial Analysis: Distribution of Trial of the Most Popular Indications by Trial Registration Year
Figure 11.15 Clinical Trial Analysis: Distribution of Trial of the Moderately Popular Indications by Trial Registration Year
Figure 11.16 Clinical Trial Analysis: Distribution of Trial of the Less Popular and Other Indications by Trial Registration Year
Figure 11.17 Clinical Trial Analysis: Distribution by Trial Phase of Development
Figure 11.18 Clinical Trial Analysis: Distribution of Trials of the Most Popular Biomarkers by Phase of Development
Figure 11.19 Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Biomarkers by Phase of Development
Figure 11.20 Clinical Trial Analysis: Distribution of Trials of the Less Popular and Other Biomarkers by Phase of Development
Figure 11.21 Clinical Trial Analysis: Distribution of Trials of the Most Popular Indications by Phase of Development
Figure 11.22 Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Indications by Phase of Development
Figure 11.23 Clinical Trial Analysis: Distribution of Trials of the Less Popular / Emerging Indications by Phase of Development
Figure 11.24 Clinical Trial Analysis: Distribution of Trials by Sponsor
Figure 11.25 Clinical Trial Analysis: Distribution of Trials of the Most Popular Biomarkers by Sponsor
Figure 11.26 Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Biomarkers by Sponsor
Figure 11.27 Clinical Trial Analysis: Distribution of Trials of the Most Popular Indications by Sponsor
Figure 11.28 Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Indications by Sponsor
Figure 11.29 Clinical Trial Analysis: Distribution by Recruitment Status
Figure 11.30 Clinical Trial Analysis: Distribution by Therapy Design
Figure 11.31 Clinical Trial Analysis: Distribution by Geography
Figure 11.32 Clinical Trial Analysis: Distribution by Enrolled Patient Population
Figure 11.33 Clinical Trial Analysis: Distribution of Trials of the Lung Cancer by Affiliated Biomarkers
Figure 11.34 Clinical Trial Analysis: Distribution of Trials of the Breast Cancer by Affiliated Biomarkers
Figure 11.35 Clinical Trial Analysis: Distribution of Trials of the Lymphoma by Affiliated Biomarkers
Figure 11.36 Clinical Trial Analysis: Distribution of Trials of the Ovarian Cancer by Affiliated Biomarkers
Figure 11.37 Clinical Trial Analysis: Distribution of Trials of the Prostate Cancer by Affiliated Biomarkers
Figure 11.38 Clinical Trial Analysis: Distribution of Trials of the Melanoma by Affiliated Biomarkers
Figure 11.39 Clinical Trial Analysis: Distribution of Trials of the Colon / Colorectal Cancer by Affiliated Biomarkers
Figure 11.40 Clinical Trial Analysis: Distribution of Trials of the Head and Neck Cancer by Affiliated Biomarkers
Figure 12.1. Global Companion Diagnostics Services Market, 2020-2030 (USD Billion)
Figure 12.2. Global Companion Diagnostics Services Market: Distribution by Type of Service Offered, 2020-2030 (USD Billion)
Figure 12.3. Global Companion Diagnostics Services Market: Distribution by Type of Analytical Technique, 2020-2030 (USD Billion)
Figure 12.4. Global Companion Diagnostics Services Market: Distribution by Region, 2020-2030 (USD Billion)
Figure 12.5. Companion Diagnostics Services Market in the North America, 2020-2030 (USD Billion)
Figure 12.6. Companion Diagnostics Services Market in the North America: Distribution by Type of Service Offered, 2020-2030 (USD Billion)
Figure 12.7. Companion Diagnostics Services Market in the North America: Distribution by Type of Analytical Technique, 2020-2030 (USD Billion)
Figure 12.8. Companion Diagnostics Services Market in Europe, 2020-2030 (USD Billion)
Figure 12.9. Companion Diagnostics Services Market in Europe: Distribution by Type of Service Offered, 2020-2030 (USD Billion)
Figure 12.10. Companion Diagnostics Services Market in Europe: Distribution by Type of Analytical Technique, 2020-2030 (USD Billion)
Figure 12.11. Companion Diagnostics Services Market in Asia, 2020-2030 (USD Billion)
Figure 12.12. Companion Diagnostics Services Market in Asia: Distribution by Type of Service Offered, 2020-2030 (USD Billion)
Figure 12.13. Companion Diagnostics Services Market in Asia: Distribution by Type of Analytical Technique, 2020-2030 (USD Billion)
Figure 12.14. Companion Diagnostics Services Market in Rest of the World, 2020-2030 (USD Billion)
Figure 12.15. Companion Diagnostics Services Market in Rest of the World: Distribution by Type of Service Offered, 2020-2030 (USD Billion)
Figure 12.16. Companion Diagnostics Services Market in Rest of the World: Distribution by Type of Analytical Technique, 2020-2030

List of Tables

Table 4.1 Companion Diagnostics Service Providers: Information on Type of Service Offered
Table 4.2 Companion Diagnostics Service Providers: Information on Type of Analytical Techniques
Table 4.3 Companion Diagnostics Service Providers: Additional Information (Regulatory Certification / Accreditation and Type of End User)
Table 5.1 Companion Diagnostic Service Providers: List of Profiled Companies
Table 5.2 Asuragen: Company Snapshot
Table 5.3 Asuragen: Recent Developments and Future Outlook
Table 5.4 Covance: Company Snapshot
Table 5.5 Covance: Recent Developments and Future Outlook
Table 5.6 Geneuity: Company Snapshot
Table 5.7 Geneuity: Recent Developments and Future Outlook
Table 5.8 MD BIOSCIENCES: Company Snapshot
Table 5.9 MD BIOSCIENCES: Recent Developments and Future Outlook
Table 5.10 ResearchDx: Company Snapshot
Table 5.11 ResearchDx: Recent Developments and Future Outlook
Table 5.12 Almac Diagnostic Services: Company Snapshot
Table 5.13 Almac Diagnostic Services: Recent Developments and Future Outlook
Table 5.14 Leica Biosystems: Company Snapshot
Table 5.15 Leica Biosystems: Recent Developments and Future Outlook
Table 5.16 R-Biopharm: Company Snapshot
Table 5.17 R-Biopharm: Recent Developments and Future Outlook
Table 5.18 Tepnel Pharma Services: Company Snapshot
Table 5.19 Tepnel Pharma Services: Recent Developments and Future Outlook
Table 5.20 BARD1 Life Sciences: Company Snapshot
Table 5.21 BARD1 Life Sciences: Recent Developments and Future Outlook
Table 5.22 BioMarCare: Company Snapshot
Table 5.23 BioMarCare Technologies: Recent Developments and Future Outlook
Table 5.24 Gencurix: Company Snapshot
Table 5.25 Gencurix: Recent Developments and Future Outlook
Table 5.26 Macrogen: Company Snapshot
Table 5.27 Macrogen: Recent Developments and Future Outlook
Table 6.1 Companion Diagnostic Service Providers: Partnerships and Collaborations, 2014-2019
Table 7.1 Companies Working on the Amyloid Beta Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 7.2 Companies Working on the Tau Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 7.3 Companies Working on the BRCA Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 7.4 Companies Working on the HER Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 7.5 Companies Working on the HR Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 7.6 Companies Working on the PD-L1 Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 7.7 Companies Working on the BRAF Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 7.8 Companies Working on the EGFR Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 7.9 Companies Working on the KRAS Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 7.10 Companies Working on the MSI Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 7.11 Companies Working on the NRAS Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 7.12 Companies Working on the CCR5 Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 7.13 Companies Working on the ALK Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 7.14 Companies Working on the EGFR Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 7.15 Companies Working on the PD-L1 Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 7.16 Companies Working on the RET Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 7.17 Companies Working on the ROS Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 7.18 Companies Working on the AST Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 7.19 Companies Working on the BRCA Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 7.20 Companies Working on the CA-125 Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 7.21 Companies Working on the PTEN Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 11.1 List of Likely Drug Candidates / Potential Collaborators for Diagnostic Developers
Table 11.2 List of Biomarkers across Moderately Popular Indications
Table 11.3 List of Biomarkers across Emerging Indications
Table 16.1. Companion Diagnostics Service Providers: Distribution by Type of Service Offered
Table 16.2. Companion Diagnostics Service Providers: Distribution by Type of Analytical Technique
Table 16.3. Companion Diagnostics Service Providers: Distribution by Type of Regulatory Accreditation / Certification
Table 16.4. Companion Diagnostics Service Providers: Distribution by Type of End User
Table 16.5. Companion Diagnostics Service Providers: Distribution by Year of Establishment
Table 16.6. Companion Diagnostics Service Providers: Distribution by Company Size
Table 16.7. Companion Diagnostics Service Providers: Distribution by Geographical Location
Table 16.8. Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2019
Table 16.9. Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.10. Partnerships and Collaborations: Year-wise Trend by Type of Partnership 2017-2019.
Table 16.11. Partnerships and Collaborations: Distribution by Type of Analytical Technique and Type of Partnership
Table 16.12. Partnerships and Collaborations: Distribution by Type of Therapeutic Area and Type of Partnership
Table 16.13. Partnerships and Collaborations: Year-wise Trend for Type of Partner
Table 16.14. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 16.15. Most Active Players: Distribution by Number of Partnerships
Table 16.16. Partnership and Collaborations: Regional Distribution
Table 16.17. Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Table 16.18. Companion Diagnostics Value Chain: Cost Distribution
Table 16.19. Clinical Trial Analysis: Distribution by Trial Registration Year
Table 16.20. Clinical Trial Analysis: Distribution of Trials of the Most Popular Biomarkers by Trial Registration Year
Table 16.21. Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Biomarkers by Trials Registration Year
Table 16.22. Clinical Trial Analysis: Distribution of Trials of the Less Popular / Preliminary Stage Biomarkers by Trial Registration Year
Table 16.23. Clinical Trial Analysis: Distribution of Trials of the Most Popular Biomarkers by Trial Registration Year
Table 16.24. Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Biomarkers by Trial Registration Year
Table 16.25. Clinical Trial Analysis: Distribution of Trials of the Less Popular and Other Biomarkers by Trial Registration Year
Table 16.26. Clinical Trial Analysis: Distribution by Most Popular Indications
Table 16.27. Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Indications
Table 16.28. Clinical Trial Analysis: Distribution of Trials of the Less Popular and Other Indications
Table 16.29. Clinical Trial Analysis: Distribution of Trial of the Most Popular Indications by Trial Registration Year
Table 16.30. Clinical Trial Analysis: Distribution of Trial of the Moderately Popular Indications by Trial Registration Year
Table 16.31. Clinical Trial Analysis: Distribution of Trial of the Less Popular and Other Indications by Trial Registration Year
Table 16.32. Clinical Trial Analysis: Distribution by Trial Phase of Development
Table 16.33. Clinical Trial Analysis: Distribution of Trials of the Most Popular Biomarkers by Phase of Development
Table 16.34. Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Biomarkers by Phase of Development
Table 16.35. Clinical Trial Analysis: Distribution of Trials of the Less Popular and Other Biomarkers by Phase of Development
Table 16.36. Clinical Trial Analysis: Distribution of Trials of the Most Popular Indications by Phase of Development
Table 16.37. Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Indications by Phase of Development
Table 16.38. Clinical Trial Analysis: Distribution of Trials of the Less Popular / Emerging Indications by Phase of Development
Table 16.39. Clinical Trial Analysis: Distribution of Trials by Sponsor
Table 16.40. Clinical Trial Analysis: Distribution of Trials of the Most Popular Biomarkers by Sponsor
Table 16.41. Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Biomarkers by Sponsor
Table 16.42. Clinical Trial Analysis: Distribution of Trials of the Most Popular Indications by Sponsor
Table 16.43. Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Indications by Sponsor
Table 16.44. Clinical Trial Analysis: Distribution by Recruitment Status
Table 16.45. Clinical Trial Analysis: Distribution by Therapy Design
Table 16.46. Global Companion Diagnostics Services Market, Base, Optimistic and Conservative Scenario, 2020-2030 (USD Billion)
Table 16.47. Global Companion Diagnostics Services Market, Base, Optimistic and Conservative Scenario: Distribution by Type of Service Offered, 2020-2030 (USD Billion)
Table 16.48. Global Companion Diagnostics Services Market, Base, Optimistic and Conservative Scenario: Distribution by Type of Analytical Technique, 2020-2030 (USD Billion)
Table 16.49. Global Companion Diagnostics Services Market, Base, Optimistic and Conservative Scenario: Distribution by Region, 2020-2030 (USD Billion)
Table 16.50. Companion Diagnostics Services Market in the North America, Base, Optimistic and Conservative Scenario, 2020-2030 (USD Billion)
Table 16.51. Companion Diagnostics Services Market in the North America: Distribution by Type of Service Offered, 2020-2030 (USD Billion)
Table 16.52. Companion Diagnostics Services Market in the North America: Distribution by Type of Analytical Technique, 2020-2030 (USD Billion)
Table 16.53. Companion Diagnostics Services Market in Europe, Base, Optimistic and Conservative Scenario, 2020-2030 (USD Billion)
Table 16.54. Companion Diagnostics Services Market in Europe: Distribution by Type of Service Offered, 2020-2030 (USD Billion)
Table 16.55. Companion Diagnostics Services Market in Europe: Distribution by Type of Analytical Technique, 2020-2030 (USD Billion)
Table 16.56. Companion Diagnostics Services Market in Asia, Base, Optimistic and Conservative Scenario, 2020-2030 (USD Billion)
Table 16.57. Companion Diagnostics Services Market in Asia: Distribution by Type of Service Offered, 2020-2030 (USD Billion)
Table 16.58. Companion Diagnostics Services Market in Asia: Distribution by Type of Analytical Technique, 2020-2030 (USD Billion)
Table 16.59. Companion Diagnostics Services Market in Rest of the World, Base, Optimistic and Conservative Scenario, 2020-2030 (USD Billion)
Table 16.60. Companion Diagnostics Services Market in Rest of the World: Distribution by Type of Service Offered, 2020-2030 (USD Billion)
Table 16.61. Companion Diagnostics Services Market in Rest of the World: Distribution by Type of Analytical Technique, 2020-2030 (USD Billion)